- Home
- VCNX
VCNX
Vaccinex Inc.
as 07-26-2024 4:00pm EST
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | ROCHESTER |
| Market Cap: | 10.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 61.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -27.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.43 - $65.10 | Next Earning Date: | 08-12-2024 |
| Revenue: | $124,000 | Revenue Growth: | -84.97% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vaccinex Inc. (VCNX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FRIEDBERG ALBERT | VCNX | Director10% Owner | May 29 '24 | Buy | $5.20 | 861 | $4,472.90 | 562,415 | SEC Form 4 |
| FRIEDBERG ALBERT | VCNX | Director10% Owner | May 29 '24 | Buy | $4.95 | 957 | $4,737.15 | 561,554 | SEC Form 4 |
| Van Strydonck, Gerald E. | VCNX | Director | Dec 26 '23 | Sell | $0.72 | 3,149 | $2,267.28 | 0 | SEC Form 4 |
| Van Strydonck, Gerald E. | VCNX | Director | Dec 8 '23 | Sell | $0.67 | 1,334 | $893.78 | 3,149 | SEC Form 4 |
Latest Vaccinex Inc. News
VCNX Breaking Stock News: Dive into VCNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
Bloomberg
2 months ago
Macron Calls French Legislative Election After Far-Right Surge
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Compare VCNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCNX Vaccinex Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.